Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITY: semaglutide for obesity in craniopharyngioma
NL-OMON27692Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of semaglutide in obesity and hypothalamic obesity (HO), sponsored by Erasmus MC. Primary endpoint: Change in BMI. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
03
Conditions
obesityhypothalamic obesity (HO)
Beyond the preview
Go deeper on NL-OMON27692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27692.